Abstract
The involvement of the glutamate-glycine activated ion channels of the NMDA receptor in various neurophysiological processes has made this ion channel the focus of intense research. The excessive release of glutamate in a variety of neuronal hypoxic conditions implicates the NMDA receptor in a number of neuropatholological states, such as stroke, chronic pain, Parkinsons disease, Alzheimers disease, ALS, and epilepsy, among others, thus making this receptor a prime drug target candidate. A variety of agents are known to be effective in opening and closing of the ion channels of this receptor, among the latter group of agents is the peptidic conantokins. Through the use of electrophysiological measurements with a number of cell types containing natural and recombinant subunits of the NMDA receptor, much knowledge is evolving regarding the mechanism of action of activators and inhibitors of the NMDA receptor ion channels. In addition, structure-function studies of the conantokins in these systems have been revealing in terms of their complimentary sites on the NMDA receptor. These relationships serve as the main focus of this review.
Keywords: NMDA Receptor, electrophysiological measurements, C-terminal residues, GLA RESIDUES IN CONANTOKIN, NR1b NR2B, hippocampal neurons
Current Drug Targets
Title: Activators and Inhibitors of the Ion Channel of the NMDA Receptor
Volume: 2 Issue: 3
Author(s): Rebecca C. Klein and Francis J. Castellino
Affiliation:
Keywords: NMDA Receptor, electrophysiological measurements, C-terminal residues, GLA RESIDUES IN CONANTOKIN, NR1b NR2B, hippocampal neurons
Abstract: The involvement of the glutamate-glycine activated ion channels of the NMDA receptor in various neurophysiological processes has made this ion channel the focus of intense research. The excessive release of glutamate in a variety of neuronal hypoxic conditions implicates the NMDA receptor in a number of neuropatholological states, such as stroke, chronic pain, Parkinsons disease, Alzheimers disease, ALS, and epilepsy, among others, thus making this receptor a prime drug target candidate. A variety of agents are known to be effective in opening and closing of the ion channels of this receptor, among the latter group of agents is the peptidic conantokins. Through the use of electrophysiological measurements with a number of cell types containing natural and recombinant subunits of the NMDA receptor, much knowledge is evolving regarding the mechanism of action of activators and inhibitors of the NMDA receptor ion channels. In addition, structure-function studies of the conantokins in these systems have been revealing in terms of their complimentary sites on the NMDA receptor. These relationships serve as the main focus of this review.
Export Options
About this article
Cite this article as:
Klein C. Rebecca and Castellino J. Francis, Activators and Inhibitors of the Ion Channel of the NMDA Receptor, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348290
DOI https://dx.doi.org/10.2174/1389450013348290 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of Specific Antibody Responses in Patients with Selective IgA
Deficiency and Ataxia Telangiectasia
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Different Food Odors Control Brain Connectivity in Impulsive Children
CNS & Neurological Disorders - Drug Targets The Role of Innate Immune System Receptors in Epilepsy Research
CNS & Neurological Disorders - Drug Targets Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Editorial [Hot Topic:Ion Channels as a Target for Drug Design (Executive Editor: Kwok-Keung Tai)]
Current Pharmaceutical Design Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Investigation of the Roles of New Antiepileptic Drugs and Serum BDNF Levels in Efficacy and Safety Monitoring and Quality of Life: A Clinical Research
Current Clinical Pharmacology NLRP3 Inflammasome Activation Leads to Epileptic Neuronal Apoptosis
Current Neurovascular Research Neuropeptide Y as an Endogenous Antiepileptic, Neuroprotective and Pro-Neurogenic Peptide
Recent Patents on CNS Drug Discovery (Discontinued) The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design A Realistic Approach for Anti-Inflammatory, Antinociceptive and Antimutagenic Activities, and Risk Assessment of the Aqueous Extract of <i>Platanus orientalis</i> L. Leaves
Current Molecular Pharmacology Children with Medical Complexity: Forwarding a Policy Agenda
Current Pediatric Reviews Liver-Brain Axis in Sporadic Alzheimer’s Disease: Role of Ten Signature Genes in a Mouse Model
CNS & Neurological Disorders - Drug Targets Structure of Glutamate Receptors
Current Drug Targets Approaches to Mitochondrial Gene Therapy
Current Gene Therapy The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research Functional Interference of Dexamethasone on Some Morphine Effects:Hypothesis for the Steroid-Opioid Interaction
Recent Patents on CNS Drug Discovery (Discontinued)